Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Arch Biopartners (Arch) announced the US Patent and Trademark Office (USPTO) has issued U.S. Patent 9,095,541 titled, "Brain Tumor Targeting Peptides", further protecting MetaMx, the Company's peptide based technology which targets brain tumour initiating cells (BTICs) and invasive glioma cells (IGCs).
Subscribe to our email newsletter
Arch management anticipates that similar patents will be issued, in due course, in various major national markets that are members of the Patent Cooperation Treaty.
This U.S. patent issued today is the second related to MetaMx. In September 2013, the USPTO issued Patent 8,530,429 bearing the same name. Both patents are based on technology invented by Dr. Stephen Robbins, Dr. Donna Senger and Dr. Jennifer Rahn at the University of Calgary who previously assigned the patents to Arch.
"We are quite pleased to see another patent get issued for MetaMx while we continue to work toward the first human trial to target and image BTICs and IGCs in patients with malignant gliomas," said Richard Muruve, CEO of Arch.
Arch Biopartners is a portfolio based biotechnology company established to develop new products and technology for unmet medical needs. The Company’s portfolio includes MetaMx, which targets brain tumor initiating cells; ABP569, a new treatment for respiratory Pseudomonas aeruginosa infections; and, Metablok, a potential treatment for sepsis and cancer metastasis.